Clinical Dermatology Review (Jan 2019)

Biologicals in the management of rheumatodermatologic conditions and beyond

  • C B Mithun,
  • B Harikrishnan

DOI
https://doi.org/10.4103/cdr.cdr_51_18
Journal volume & issue
Vol. 3, no. 1
pp. 41 – 46

Abstract

Read online

Biologicals are synthesized from living cells by biotechnology methods and typically include monoclonal antibodies and fusion proteins targeted against pathogenic cytokines, B or T cells, or its receptors. A biosimilar is a cheaper, manufactured product which is almost the same as biological. Appropriate patient selection is the key consideration before starting biologicals. Screening for tuberculosis is a must, except in case of rituximab. Tumor-necrosis-factor alpha inhibitors, interleukin (IL)-17A antagonists, anti-CD6 monoclonal antibodies (mAbs), and anti-IL-6 mAbs are discussed here for various indications.

Keywords